Form 4: Mineralys Therapeutics CFO Sells Over 10,000 Shares Under Pre-Arranged 10b5-1 Plan

Mineralys Therapeutics' CFO and Secretary, Adam Scott Levy, sold 10,758 shares of common stock on July 11, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Adam Scott Levy, the Chief Financial Officer and Secretary of Mineralys Therapeutics, Inc. (MLYS), reported a transaction involving the company's common stock.
• On July 11, 2025, Mr. Levy sold 10,758 shares of common stock.
• The shares were sold at a weighted-average price of $14.4501 per share, with individual transaction prices ranging from $14.3012 to $14.6546.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan that Mr. Levy adopted on November 14, 2023.
• Following this reported transaction, Adam Scott Levy beneficially owns 206,612 shares of Mineralys Therapeutics common stock.
• The reported beneficial ownership balance includes 2,030 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

Sentiment

Score: 5

Explanation: The document reports a pre-planned sale of shares by a company officer, which is a routine transaction under a 10b5-1 plan and does not inherently indicate a negative outlook on the company's future. It is a neutral event.

Negatives

• CFO Adam Scott Levy sold 10,758 shares of common stock, reducing his direct beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The transaction represents a reduction in direct insider ownership, though it was executed under a pre-arranged trading plan, which typically mitigates concerns about opportunistic selling.

Key Dates

Keywords

Mineralys Therapeutics, MLYS, Adam Scott Levy, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Beneficial Ownership